🇺🇸 FDA
Patent

US 9763974

Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

granted A61KA61K31/715A61K31/736

Quick answer

US patent 9763974 (Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase) held by GALECTIN THERAPEUTICS, INC. expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GALECTIN THERAPEUTICS, INC.
Grant date
Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/715, A61K31/736, A61K31/738, A61K45/06